Under construction – not a live service

Skip to content

Frontlight Research

Institution

AdventHealth Orlando

Orlando, United StatesWebsite

165running trials
73closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

No trial has been confirmed here yet.

Running trials

Recruiting
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
NCT07845617· Source
Not yet recruiting
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
NCT07814417· Phase 2· Source
Recruiting
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
NCT07764146· Phase 1· Source
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370· Phase 1· Source
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030· Source
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Source
Recruiting
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183· Phase 2· Source
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Source
Recruiting
CCM OPEN HF Registry
NCT07112924· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Source
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996· Phase 3· Source
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· Phase 3· Source
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· Source
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632· Source
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Source
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362· Phase 2· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Source
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· Source
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· Source
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463· Phase 2· Source
Active, not recruiting
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145· Phase 2· Source
Active, not recruiting
ASCEND CSP IDE Study
NCT06830746· Source
Active, not recruiting
TECTONIC CAD IVL IDE Study
NCT06885177· Source
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Source
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126· Phase 3· Source
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122· Phase 3· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Source
Active, not recruiting
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310· Phase 2· Source
Active, not recruiting
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· Phase 3· Source
Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
NCT06619561· Phase 2· Source
Active, not recruiting
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192· Phase 2· Source
Active, not recruiting
Abbott Medical - VERITAS Study
NCT06707688· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Source
Active, not recruiting
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
NCT06631521· Phase 1· Source
Recruiting
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· Phase 2· Source
Active, not recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· Phase 2· Source
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· Source
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141· Phase 3· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Source
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· Phase 2/3· Source
Active, not recruiting
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
NCT06414603· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Source
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· Phase 3· Source
Recruiting
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
NCT05442216· Phase 2· Source
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· Source
Enrolling by invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615· Source
Active, not recruiting
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06318273· Phase 1· Source

Showing 50 of 165.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
NCT06676072· Source
Completed
VOLT-AF IDE Clinical Study
NCT06223789· Source
Completed
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
NCT06313528· Phase 1· Source
Completed
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271· Phase 1· Source
Completed
Nirogacestat in Ovarian Granulosa Cell Tumors
NCT05348356· Phase 2· Source
Terminated
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
NCT04871529· Phase 2· Source
Completed
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
NCT04945460· Phase 2· Source
Completed
Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
NCT05120193· Source
Completed
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
NCT05104567· Phase 2· Source
Terminated
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT04506086· Phase 4· Source
Completed
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT04815720· Phase 1/2· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Source
Completed
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
NCT04732221· Phase 2/3· Source
Completed
Breethe Abiomed Recovery RegisTry (BART)
NCT05473130· Source
Completed
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
NCT04484142· Phase 2· Source
Terminated
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT04659603· Phase 2· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT04644237· Phase 2· Source
Recruiting
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576· Phase 2· Source
Terminated
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
NCT04585815· Phase 1/2· Source
Completed
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT04396860· Phase 2/3· Source
Completed
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
NCT04442295· Phase 1/2· Source
Terminated
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
NCT04502316· Source
Completed
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
NCT04388475· Phase 2· Source
Terminated
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
NCT03199885· Phase 3· Source
Completed
Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
NCT03729830· Source
Completed
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414· Phase 3· Source
Completed
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03526250· Phase 2· Source
Completed
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
NCT03595059· Phase 1· Source
Completed
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· Phase 3· Source
Completed
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450· Source
Completed
EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study
NCT03298477· Source
Completed
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678· Phase 2· Source
Completed
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213665· Phase 2· Source
Completed
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03220035· Phase 2· Source
Completed
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03233204· Phase 2· Source
Completed
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358· Phase 2· Source
Completed
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NCT02973789· Phase 3· Source
Completed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116· Phase 1/2· Source
Completed
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
NCT02717507· Phase 2· Source
Completed
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470091· Phase 2· Source
Completed
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT02180867· Phase 2/3· Source
Completed
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209· Phase 3· Source
Completed
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT01979536· Phase 2· Source
Completed
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
NCT01798004· Phase 1· Source
Completed
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
NCT01553149· Phase 2· Source
Completed
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
NCT01602666· Phase 2· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049· Phase 3· Source
Completed
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01371981· Phase 3· Source
Completed
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
NCT01236560· Phase 2/3· Source
Completed
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
NCT01231906· Phase 3· Source

Showing 50 of 73.

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Gastroparesis4 works · 1 trial

Institution data: ROR 02n1cyj49 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – AdventHealth Orlando: trials and research groups – Frontlight Research